Published in Clin Rheumatol on December 15, 2013
Epidemiology of neurological manifestations in Sjögren's syndrome: data from the French ASSESS Cohort. RMD Open (2016) 0.82
Cognition, depression, fatigue, and quality of life in primary Sjögren's syndrome: correlations. Brain Behav (2016) 0.79
Impact of pain on cognitive functions in primary Sjögren syndrome with small fiber neuropathy: 10 cases and a literature review. Medicine (Baltimore) (2017) 0.75
The Social Readjustment Rating Scale. J Psychosom Res (1967) 22.11
The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description. Arch Gen Psychiatry (1992) 21.60
The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol (1989) 13.32
American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken) (2012) 4.82
Sjögren's syndrome. Lancet (2005) 4.81
Clinical manifestations and early diagnosis of Sjögren syndrome. Arch Intern Med (2004) 3.03
Computerized assessment in neuropsychiatry using CANTAB: discussion paper. J R Soc Med (1992) 3.00
Sensitivity to triazolam in the elderly. N Engl J Med (1991) 2.73
Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Medicine (Baltimore) (2004) 2.54
Treatment of primary Sjögren syndrome: a systematic review. JAMA (2010) 2.37
Oral involvement in primary Sjögren syndrome. J Am Dent Assoc (2008) 1.62
The National Adult Reading Test as a measure of premorbid intelligence: a comparison with estimates derived from demographic variables. J Int Neuropsychol Soc (2002) 1.59
Sjögren's syndrome comes of age. Semin Arthritis Rheum (1999) 1.43
Dose-dependent pharmacokinetics and psychomotor effects of caffeine in humans. J Clin Pharmacol (1997) 1.42
Effects of modafinil on sustained attention performance and quality of life in OSA patients with residual sleepiness while being treated with nCPAP. Sleep Med (2003) 1.36
Use of oral reading to estimate premorbid intellectual and neuropsychological functioning. J Int Neuropsychol Soc (1999) 1.18
Peripheral nervous system manifestations of Sjögren syndrome: clinical patterns, diagnostic paradigms, etiopathogenesis, and therapeutic strategies. Neurologist (2010) 1.16
Neurological and neuropsychiatric dysfunction in primary Sjögren's syndrome. Acta Neurol Scand (1994) 1.15
Health-related quality of life in primary Sjögren's syndrome, rheumatoid arthritis and fibromyalgia compared to normal population data using SF-36. Scand J Rheumatol (2000) 1.14
CANTAB battery: proposed utility in neurotoxicology. Neurotoxicol Teratol (1997) 1.13
Primary Sjögren's Syndrome: health experiences and predictors of health quality among patients in the United States. Health Qual Life Outcomes (2009) 1.11
Fatigue in primary Sjögren's syndrome. Ann Rheum Dis (1998) 1.08
CNS involvement in primary Sjögren's syndrome: prevalence, clinical aspects, diagnostic assessment and therapeutic approach. CNS Drugs (2001) 1.05
Treatment of primary Sjögren's syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results. Arthritis Rheum (2003) 1.05
Primary Sjogren's syndrome: too dry and too tired. Rheumatology (Oxford) (2010) 1.00
Central nervous system disease in Sjögren's syndrome. New insights into immunopathogenesis. Rheum Dis Clin North Am (1992) 0.96
Anxiety and depression in patients with primary Sjögren's syndrome. J Rheumatol (2000) 0.96
Pharmacokinetic determinants of dynamic differences among three benzodiazepine hypnotics. Flurazepam, temazepam, and triazolam. Arch Gen Psychiatry (1989) 0.95
Sjögren's syndrome: a review of aetiology, pathogenesis, diagnosis and management. Aust Dent J (2010) 0.94
CNS Sjögren's syndrome: an underrecognized and underappreciated neuropsychiatric disorder. J Neuropsychiatry Clin Neurosci (1999) 0.94
Cognitive function and 99mTc-ECD brain SPECT are significantly correlated in patients with primary Sjogren syndrome: a case-control study. Ann Rheum Dis (2010) 0.90
Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. J Clin Psychiatry (2003) 0.89
Primary Sjogren's syndrome: cognitive symptoms, mood, and cognitive performance. Acta Neurol Scand (2011) 0.89
Comparative single-dose kinetics and dynamics of lorazepam, alprazolam, prazepam, and placebo. Clin Pharmacol Ther (1988) 0.89
Nutrient intake in women with primary and secondary Sjögren's syndrome. Eur J Clin Nutr (2003) 0.88
A five-year prospective study of fatigue in primary Sjögren's syndrome. Arthritis Res Ther (2011) 0.85
Psychological well-being in patients with primary Sjögren's syndrome. Clin Exp Rheumatol (2001) 0.85
Fatigue in daily life in patients with primary Sjögren's syndrome and systemic lupus erythematosus. Ann N Y Acad Sci (2002) 0.83
Pharmacokinetics and pharmacodynamics of diphenhydramine 25 mg in young and elderly volunteers. J Clin Pharmacol (1998) 0.80
Treatment of depression with fluoxetine in corticosteroid-dependent central nervous system Sjögren's syndrome. Psychosomatics (1993) 0.80
Computerized methods of neuropsychological assessment. Br J Hosp Med (1997) 0.78
Oral pilocarpine for symptomatic relief of dry mouth and dry eyes in patients with Sjögrens syndrome. Adv Exp Med Biol (1998) 0.76
Effective treatment of neuropsychological deficits in Sjögren's syndrome. Appl Neuropsychol (2005) 0.75
Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet (2010) 2.32
Reversal of soft-tissue local anesthesia with phentolamine mesylate in adolescents and adults. J Am Dent Assoc (2008) 1.81
Depression is associated with low plasma Abeta42 independently of cardiovascular disease in the homebound elderly. Int J Geriatr Psychiatry (2007) 1.81
UGT1A1 polymorphisms are important determinants of dietary carcinogen detoxification in the liver. Hepatology (2005) 1.72
Vitamin D is associated with cognitive function in elders receiving home health services. J Gerontol A Biol Sci Med Sci (2009) 1.60
Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab Dispos (2005) 1.57
Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics (2004) 1.50
Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. Clin Pharmacol Ther (2005) 1.45
Balancing efficacy and safety in the use of oral sedation in dental outpatients. J Am Dent Assoc (2006) 1.42
Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. Br J Clin Pharmacol (2003) 1.40
Evaluation of 3'-azido-3'-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab Dispos (2003) 1.38
Cardiovascular disease and cognitive function in maintenance hemodialysis patients. Am J Kidney Dis (2011) 1.35
Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab Dispos (2003) 1.34
Frequency of and risk factors for poor cognitive performance in hemodialysis patients. Neurology (2013) 1.34
In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos (2003) 1.33
The effect of grapefruit juice on drug disposition. Expert Opin Drug Metab Toxicol (2011) 1.28
Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics (2004) 1.23
The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet (2005) 1.22
Anatomic brain disease in hemodialysis patients: a cross-sectional study. Am J Kidney Dis (2012) 1.21
UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver. J Pharmacol Exp Ther (2004) 1.21
Pharmacokinetics of high-dose oral thiamine hydrochloride in healthy subjects. BMC Clin Pharmacol (2012) 1.20
Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice. Clin Pharmacol Ther (2003) 1.19
Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis. PLoS One (2013) 1.19
Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors. J Clin Oncol (2011) 1.18
Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation. J Clin Pharmacol (2008) 1.17
Gender differences in pharmacokinetics and pharmacodynamics of zolpidem following sublingual administration. J Clin Pharmacol (2013) 1.16
Macular pigment optical density is related to cognitive function in older people. Age Ageing (2014) 1.13
Inhibition of human cytochromes P450 by components of Ginkgo biloba. J Pharm Pharmacol (2004) 1.13
Simple and rapid liquid chromatography method for determination of efavirenz in plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 1.12
Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. Pharm Res (2002) 1.11
UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). J Pharmacol Exp Ther (2005) 1.11
Executive dysfunction in homebound older people with diabetes mellitus. J Am Geriatr Soc (2006) 1.09
Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques. J Clin Pharmacol (2002) 1.08
Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein. AIDS (2003) 1.07
Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. Drug Metab Dispos (2002) 1.06
The UDP-glucuronosyltransferase (UGT) 1A polymorphism c.2042C>G (rs8330) is associated with increased human liver acetaminophen glucuronidation, increased UGT1A exon 5a/5b splice variant mRNA ratio, and decreased risk of unintentional acetaminophen-induced acute liver failure. J Pharmacol Exp Ther (2013) 1.05
Relationship between Serum and Brain Carotenoids, α-Tocopherol, and Retinol Concentrations and Cognitive Performance in the Oldest Old from the Georgia Centenarian Study. J Aging Res (2013) 1.03
Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir. J Pharm Pharmacol (2003) 1.01
Reversal of soft-tissue local anesthesia with phentolamine mesylate in pediatric patients. J Am Dent Assoc (2008) 1.01
Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies. Clin Pharmacol Ther (2006) 0.99
Validation of serotonin (5-hydroxtryptamine) as an in vitro substrate probe for human UDP-glucuronosyltransferase (UGT) 1A6. Drug Metab Dispos (2003) 0.98
Pharmacologic consideration for the use of antiretroviral agents in the elderly. J Clin Pharmacol (2008) 0.98
Pomegranate juice does not impair clearance of oral or intravenous midazolam, a probe for cytochrome P450-3A activity: comparison with grapefruit juice. J Clin Pharmacol (2007) 0.98
Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers. J Clin Psychopharmacol (2007) 0.97
UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: I. Identification of polymorphisms in the 5'-regulatory and exon 1 regions, and association with human liver UGT1A6 gene expression and glucuronidation. J Pharmacol Exp Ther (2005) 0.97
Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir. J Clin Pharmacol (2002) 0.97
Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials. J Clin Pharmacol (2006) 0.96
From disordered eating to addiction: the "food drug" in bulimia nervosa. J Clin Psychopharmacol (2012) 0.96
Design of the Prevention of Adult Caries Study (PACS): a randomized clinical trial assessing the effect of a chlorhexidine dental coating for the prevention of adult caries. BMC Oral Health (2010) 0.96
Induction of P-glycoprotein expression and activity by ritonavir in bovine brain microvessel endothelial cells. J Pharm Pharmacol (2007) 0.96
Pharmacokinetics of lidocaine with epinephrine following local anesthesia reversal with phentolamine mesylate. Anesth Prog (2008) 0.95
Rapid assessment of P-glycoprotein inhibition and induction in vitro. Pharm Res (2003) 0.95
Influence of fruit juices on drug disposition: discrepancies between in vitro and clinical studies. Expert Opin Drug Metab Toxicol (2008) 0.95
Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate. Clin Pharmacol Ther (2004) 0.95
Serum concentrations and clinical effects of atorvastatin in patients taking grapefruit juice daily. Br J Clin Pharmacol (2011) 0.94
Drug metabolism and drug interactions: application and clinical value of in vitro models. Curr Drug Metab (2003) 0.94
Role of the nuclear receptor pregnane X receptor in acetaminophen hepatotoxicity. Drug Metab Dispos (2005) 0.92
Pharmocokinetics and pharmacodynamics of single-dose triazolam: electroencephalography compared with the Digit-Symbol Substitution Test. Br J Clin Pharmacol (2005) 0.92
Validity of estimated dietary eicosapentaenoic acid and docosahexaenoic acid intakes determined by interviewer-administered food frequency questionnaire among older adults with mild-to-moderate cognitive impairment or dementia. Am J Epidemiol (2009) 0.92
Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir. Clin Pharmacol Ther (2006) 0.91
The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver. Drug Metab Dispos (2006) 0.91
Role of NADPH-cytochrome P450 reductase and cytochrome-b5/NADH-b5 reductase in variability of CYP3A activity in human liver microsomes. Drug Metab Dispos (2008) 0.91
Grapefruit-medication interactions. CMAJ (2013) 0.91
Factors influencing midazolam hydroxylation activity in human liver microsomes. Drug Metab Dispos (2006) 0.90
Zolpidem pharmacokinetic properties in young females: influence of smoking and oral contraceptive use. J Clin Pharmacol (2002) 0.90
Kinetics and EEG effects of midazolam during and after 1-minute, 1-hour, and 3-hour intravenous infusions. J Clin Pharmacol (2004) 0.90
Human pregnane X receptor: genetic polymorphisms, alternative mRNA splice variants, and cytochrome P450 3A metabolic activity. J Clin Pharmacol (2006) 0.90
Are women with Sjögren's syndrome androgen-deficient? J Rheumatol (2003) 0.89
Dynamics and kinetics of a modified-release formulation of zolpidem: comparison with immediate-release standard zolpidem and placebo. J Clin Pharmacol (2006) 0.89
Nefazodone treatment of cocaine dependence with comorbid depressive symptoms. Addiction (2005) 0.89
Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors. Drug Metab Dispos (2002) 0.89
Role of CYP3A and CYP2E1 in alcohol-mediated increases in acetaminophen hepatotoxicity: comparison of wild-type and Cyp2e1(-/-) mice. Drug Metab Dispos (2007) 0.89
Mechanism of cytochrome P450-3A inhibition by ketoconazole. J Pharm Pharmacol (2011) 0.89
The absence of an interaction between warfarin and cranberry juice: a randomized, double-blind trial. J Clin Pharmacol (2009) 0.88
Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2. J Clin Pharmacol (2007) 0.88
Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. J Clin Pharmacol (2003) 0.88
Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase. Br J Clin Pharmacol (2009) 0.88
Systemic pharmacokinetics and cerebrospinal fluid uptake of intravenous ceftriaxone in patients with amyotrophic lateral sclerosis. J Clin Pharmacol (2014) 0.87
Effect of a herbal extract containing curcumin and piperine on midazolam, flurbiprofen and paracetamol (acetaminophen) pharmacokinetics in healthy volunteers. Br J Clin Pharmacol (2013) 0.87
The effect of age on P-glycoprotein expression and function in the Fischer-344 rat. J Pharmacol Exp Ther (2004) 0.87
Clinically important drug interactions with zopiclone, zolpidem and zaleplon. CNS Drugs (2003) 0.87
Fentanyl clearance and volume of distribution are increased in patients with major burns. J Clin Pharmacol (2007) 0.86
Ritonavir greatly impairs CYP3A activity in HIV infection with chronic viral hepatitis. J Acquir Immune Defic Syndr (2008) 0.86
Hyperforin plasma level as a marker of treatment adherence in the National Institutes of Health Hypericum Depression Trial. J Clin Psychopharmacol (2005) 0.86